6-Chlorochrysene | 95791-46-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 菲及其衍生物
• 英文名称: 6-Chlorochrysene
• 英文别名: 6-chloro-chrysene；6-Chlor-chrysen
• CAS: 95791-46-1
• 化学式: C₁₈H₁₁Cl
• 分子量: 262.738
• InChiKey: LVKLJLYFIFXBKM-UHFFFAOYSA-N

物化性质

• 沸点：
  465.3±14.0 °C(Predicted)
• 密度：
  1.289±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  6.3
• 重原子数：
  19
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  6-Chlorochrysene 在 氯氟磺酰 、 五氟化锑 、 氟磺酸 作用下， 生成
  参考文献：
  名称：

  Stable Ion Studies of the Chrysene Skeleton. Protonation of Chrysene, 6-Halochrysenes, 6-Acetylchrysene, and 4H-Cyclopenta[def]chrysene:  NMR Studies of Charge Distribution in Chrysenium Cations and AM1 Calculations

  摘要：

  Chrysene (1), 6-fluorochrysene (2), 6-chlorochrysene (3), and 6-bromochrysene (4) are cleanly monoprotonated in FSO3H . SbF5 (ca. 10:1)/SO2ClF at the C-12 position. 6-Acetylchrysene (5) is CO-protonated in FSO3H/SO2ClF with significant charge delocalization into the chrysene and provides a model for a C-6-protonated chrysenium cation. 4H-Cyclopenta[def]chrysene (6) is protonated at C-5 (site of bromination and acetylation). The observed chrysenium (methanochrysenium) cations are those predicted by AM1 to have the lowest energies. The NMR characteristics of the resulting arenium ions are discussed and the he Delta delta Cs-13 are compared with AM1 calculated changes in charges [Delta q(c) = q(c)(ion) - q(c)(neutral)]. Possible relationships between the charge delocalization path in chrysenium ions and metabolic activation of chrysenes by electrophilic pathways via the bay-region epoxide ring opening (--> PAH-DNA adduct) are evaluated.

  DOI：

  10.1021/jo9620730
• 作为产物：
  描述：

  chrysene-6-carbonyl chloride 在 RhCl(PPh₃)3 作用下， 生成 6-Chlorochrysene
  参考文献：
  名称：

  Decarbonylation of aromatic carbonyl compounds catalyzed by rhodium complexes

  摘要：

  DOI：

  10.1021/ja00986a017

文献信息

• Lethality and EROD-inducing potency of chlorinated chrysene in chick embryos
  作者：E. Gustafsson、B. Brunström、U. Nilsson

  DOI：10.1016/0045-6535(94)90398-0

  日期：1994.11

  chick embryos with coplanar PCBs. Chlorinated chrysene was also much more potent than chrysene as an inducer of EROD in a 72-hour test in chick embryos in ovo and in chick embryo liver in vitro. It seems that the mechanism of toxicity of chlorinated chrysene in chick embryos is similar to that of the coplanar PCBs and other Ah receptor ligands. The effects of the chlorinated mixture were mainly accounted

  苯经过非特异性氯化处理，并研究了所形成混合物的毒性。在雏鸡胚胎的2周测试中，就胚胎致死率，EROD和AHH诱导而言，氯化混合物比母体化合物的效力要强得多。氯化引起的异常，包括水肿和喙缺陷，类似于先前用共面多氯联苯处理雏鸡后发现的异常。在72个小时的卵内雏鸡胚胎和体外雏鸡肝脏中，氯化的EROE的诱导能力也比CES强。看来，氯化雏鸡胚中毒的机理与共面多氯联苯和其他Ah受体配体的毒性机理相似。氯化混合物的影响主要是由6-氯丙烯和6,12-二氯丙烯引起的。
• Crysene derivatives
  申请人：Burroughs Wellcome Co.

  公开号：US04719046A1

  公开（公告）日：1988-01-12

  The present invention relates to compounds of formula (I) ArCH.sub.2 R.sup.1 (I) or a monomethyl or a monoethyl ether thereof (the compound of formula (I) including these ethers may contain no more than 30 carbon atoms in total); ethers, esters thereof; acid addition salts thereof; wherein Ar is a chrysene or substituted chrysene ring system; R.sup.1 contains not more than eight carbon atoms and is a group ##STR1## wherein m is 0 or 1; R.sup.5 is hydrogen; R.sup.6 and R.sup.7 are the same or different and each is hydrogen or C.sub.1-3 alkyl optionally substituted by hydroxy; R.sup.8 and R.sup.9 are the same or different and each is hydrogen or C.sub.1-3 alkyl, ##STR2## is a five- or six-membered saturated carbocyclic ring; R.sup.10 is hydrogen, methyl or hydroxymethyl; R.sup.11, R.sup.12 and R.sup.13 are the same or different and each is hydrogen or methyl; R.sup.14 is hydrogen, methyl, hydroxy, or hydroxymethyl.

  本发明涉及化合物的公式（I）ArCH.sub.2 R.sup.1（I）或其单甲基或单乙基醚（公式（I）的这些醚物可能总共不超过30个碳原子）；它们的醚，酯；酸盐；其中Ar是蒽或取代蒽环系；R.sup.1含有不超过八个碳原子，并且是一个组##STR1##其中m为0或1；R.sup.5为氢；R.sup.6和R.sup.7相同或不同，每个都是氢或C.sub.1-3烷基，可以选择性地被羟基取代；R.sup.8和R.sup.9相同或不同，每个都是氢或C.sub.1-3烷基，##STR2##是一个五元或六元饱和碳环；R.sup.10是氢，甲基或羟甲基；R.sup.11，R.sup.12和R.sup.13相同或不同，每个都是氢或甲基；R.sup.14是氢，甲基，羟基或羟甲基。
• Crysene compound
  申请人：Burroughs Wellcome Co.

  公开号：US04719048A1

  公开（公告）日：1988-01-12

  The present invention relates to compounds of formula (I) ArCH.sub.2 R.sup.1 (I) or a monomethyl or a monoethyl ether thereof (the compound of formula (I) including these ethers may contain no more than 30 carbon atoms in total); ethers, esters thereof; acid addition salts thereof; wherein Ar is a chrysene or substituted chrysene ring system; R.sup.1 contains not more than eight carbon atoms and is a group ##STR1## wherein m is 0 or 1; R.sup.5 is hydrogen; R.sup.6 and R.sup.7 are the same or different and each is hydrogen or C.sub.1-3 alkyl optionally substituted by hydroxy; R.sup.8 and R.sup.9 are the ame or different and each is hydrogen or C.sub.1-3 alkyl; ##STR2## is a five- or six-membered saturated carbocyclic ring; R.sup.10 is hydrogen, methyl or hydroxymethyl; R.sup.11, R.sup.12 and R.sup.13 are the same or different and each is hydrogen or methyl; R.sup.14 is hydrogen, methyl, hydroxy, or hydroxymethyl.

  本发明涉及化合物的公式（I）ArCH.sub.2R.sup.1（I）或其单甲基或单乙基醚（公式（I）的化合物包括这些醚，在总共不超过30个碳原子的情况下）;其醚，酯;酸加成盐;其中Ar是蒽或取代蒽环系统; R.sup.1含有不超过八个碳原子，是一个组##STR1##其中m为0或1; R.sup.5为氢; R.sup.6和R.sup.7相同或不同，每个都是氢或C.sub.1-3烷基，可以选择性地被羟基取代; R.sup.8和R.sup.9相同或不同，每个都是氢或C.sub.1-3烷基; ##STR2##是一个五元或六元饱和碳环; R.sup.10为氢，甲基或羟甲基; R.sup.11，R.sup.12和R.sup.13相同或不同，每个都是氢或甲基; R.sup.14为氢，甲基，羟基或羟甲基。
• Chrysene compound
  申请人：Burroughs Wellcome Co.

  公开号：US04810727A1

  公开（公告）日：1989-03-07

  The present invention relates to compounds of formula (I) ArCH.sub.2 R.sup.1 (I) or a monomethyl or a monoethyl ether thereof (the compound of formula (I) including these ethers may contain no more than 30 carbon atoms in total); ethers, esters thereof; acid addition salts thereof; wherein Ar is a chrysene or substituted chrysene ring system; R.sup.1 contains not more than eight carbon atoms and is a group ##STR1## wherein m is 0 or 1; R.sup.5 is hydrogen; R.sup.6 and R.sup.7 are the same or different and each is hydrogen or C.sub.1-3 alkyl optionally substituted by hydroxy; R.sup.8 and R.sup.9 are the same or different and each is hydrogen or C.sub.1-3 alkyl; --C--C-- is a five- or six-membered saturated carbocyclic ring; R.sup.10 is hydrogen, methyl or hydroxymethyl; R.sup.11, R.sup.12 and R.sup.13 are the same or different and each is hydrogen or methyl; R.sup.14 is hydrogen, methyl, hydroxy, or hydroxymethyl.

  本发明涉及式(I) ArCH.sub.2R.sup.1(I)化合物或其单甲基或单乙基醚（式(I)化合物包括这些醚，总碳原子数不超过30）；醚，酯；其酸加成盐；其中Ar是蒽或取代蒽环系统；R.sup.1不超过八个碳原子，是一个基团##STR1##其中m为0或1；R.sup.5是氢；R.sup.6和R.sup.7相同或不同，每个是氢或C.sub.1-3烷基，可选地被羟基取代；R.sup.8和R.sup.9相同或不同，每个是氢或C.sub.1-3烷基；--C--C--是一个五元或六元饱和碳环；R.sup.10是氢，甲基或羟甲基；R.sup.11，R.sup.12和R.sup.13相同或不同，每个是氢或甲基；R.sup.14是氢，甲基，羟基或羟甲基。
• Chrysene derivatives
  申请人：Burroughs Wellcome Co.

  公开号：US04829090A1

  公开（公告）日：1989-05-09

  The present invention relates to compounds of formula (I) ArCH.sub.2 R.sup.1 (I) or a monomethyl or a monoethyl ether thereof (the compound of formula (I) including these ethers may contain no more than 30 carbon atoms in total); ethers, esters thereof; acid addition salts thereof; wherein Ar is a chrysene or substituted chrysene ring system; R.sup.1 contains not more than eight carbon atoms and is a group ##STR1## wherein m is 0 or 1; R.sup.5 is hydrogen; R.sup.6 and R.sup.7 are the same or different and each is hydrogen or C.sub.1-3 alkyl optionally substituted by hydroxy; R.sup.8 and R.sup.9 are the same or different and each is hydrogen or C.sub.1-3 alkyl; ##STR2## is a five- or six-membered saturated carbocyclic ring; R.sup.10 is hydrogen, methyl or hydroxymethyl; R.sup.11, R.sup.12 and R.sup.13 are the same or different and each is hydrogen or methyl; R.sup.14 is hydrogen, methyl, hydroxy, or hydroxymethyl.

  本发明涉及式(I)的化合物 ArCH.sub.2 R.sup.1(I)或其甲基或乙基单醚（包括这些醚的式(I)化合物总共不超过30个碳原子）；它们的醚、酯；它们的酸加成盐；其中Ar是蒽或取代蒽环系统；R.sup.1不含超过八个碳原子，是一个基团##STR1##其中m为0或1；R.sup.5为氢；R.sup.6和R.sup.7相同或不同，每个都是氢或C.sub.1-3烷基，可选地被羟基取代；R.sup.8和R.sup.9相同或不同，每个都是氢或C.sub.1-3烷基；##STR2##是一个五元或六元饱和碳环；R.sup.10为氢、甲基或羟甲基；R.sup.11、R.sup.12和R.sup.13相同或不同，每个都是氢或甲基；R.sup.14为氢、甲基、羟基或羟甲基。